Home > Groups > ISPM_UniBe_GetReal

ISPM_UniBe_GetReal

Recently Added Items

Title	Added By	Updated On
The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study	nhummel	Mar 3, 2015 11:23:07 AM
Modeling the progression of rheumatoid arthritis: A two-country model to estimate costs and consequences of rheumatoid arthritis	nhummel	Mar 3, 2015 11:21:14 AM
The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis	nhummel	Mar 3, 2015 8:51:03 AM
Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol	nhummel	Mar 3, 2015 8:33:56 AM
A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis	nhummel	Mar 3, 2015 8:33:35 AM
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective	nhummel	Mar 3, 2015 8:25:34 AM
Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands: Cost Effectiveness of TNF-Blocking Treatment	nhummel	Mar 3, 2015 8:23:25 AM
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice	nhummel	Mar 3, 2015 8:14:16 AM
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment	nhummel	Mar 2, 2015 5:05:54 PM
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis	nhummel	Mar 2, 2015 4:03:38 PM

See all 246 items for this group in the Group Library.

Owner: KleaPan
Registered: 2014-05-15
Type: Public
Membership: Closed

Members (8)